Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
August 08, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
July 28, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
June 30, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
June 29, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
June 28, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
ROIV
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
June 25, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
June 24, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Third-Quarter 2022 Dividend
June 23, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
June 20, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
VALN
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
June 17, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
June 14, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Completes Acquisition of ReViral
June 09, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 09, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 08, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
June 06, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer
June 04, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Provides Update on Ownership Interest in Haleon
June 01, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability
May 31, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
May 26, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
May 25, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries
May 25, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
May 24, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
May 17, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer to Acquire Biohaven Pharmaceuticals
May 10, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BHVN
PFE
Pfizer Reports First-Quarter 2022 Results
May 03, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Second-Quarter 2022 Dividend
April 28, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
April 27, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BHVN
PFE
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
April 26, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
VALN
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
April 19, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.